Mr. Payton Nyquvest reports

NUMINUS WELLNESS INC. REPORTS Q3 2023 RESULTS

Numinus Wellness Inc. has released its financial results for the three months ended May 31, 2023 (Q3 2023).

"We're on the verge of a pivotal turning point for the psychedelics sector -- with MDMA [3,4-methylenedioxy-N-methamphetamine]-assisted therapy on a path to FDA [Food and Drug Administration] approval, long-form psychedelic-assisted therapy receiving an insurance pay code, and cultural awareness and support for these treatments building," said Payton Nyquvest, founder and chief executive officer. "Within this, Numinus is focusing on building scale and sector partnerships to deliver best-in-class clinical infrastructure and practitioner training programs to support greater patient access to these important therapies. Our recently announced experiential training partnership with MAPS [Multidisciplinary Association for Psychedelic Studies] is a great example of how Numinus is uniquely positioned within the sector."

Mr. Nyquvest continued: "We took meaningful steps during our fiscal third quarter to best align our business with future opportunities related to the expected approval of MDMA-assisted therapy. These activities included launching the Numinus Network licensing program, focusing capital and people resources towards revenue-producing business lines, and preparing for expanded insurance payor coverage of psychedelic-assisted therapies. Collectively, we believe these actions will improve the productivity of our clinics and training offerings, drive higher long-term margins, and extend our cash runway. We expect the true impact of these changes will begin to be demonstrated in the next few months."

Revenue

Revenues grew 12.6 per cent from the prior quarter to $6-million in Q3 2023, due mostly to growth in client appointments and strong performance by Cedar Clinical Research (CCR). Compared with the same quarter last year, revenues grew 713.3 per cent.

Gross margin

Sequentially, gross margin declined 480 basis points in Q3 2023 to 34.5 per cent from 39.3 per cent in Q2 2023, due to an increased number of full-time practitioners (rather than part-time contractors) and the performance of certain clinic locations, which the company is actively looking to optimize. Gross margin grew 1,010 basis points in Q3 2023 compared with 24.4 per cent in Q3 2022. The improvement in gross margin compared with Q3 last year is due mostly to increased client appointments and higher clinic utilization rates. Gross profit was $2.1-million in Q3 2023, in line with the previous quarter, but a significant increase compared with gross profit of $200,000 in Q3 2022.

Operating expenditures

During the third quarter, Numinus undertook several initiatives to lower its cash expenses and refocus operations on revenue-producing activities, including the renegotiation of vendor contracts, reducing headcount in non-revenue generating departments and deferring non-urgent projects. In addition, the company reallocated capital and people resources toward expansion initiatives expected to drive long-term revenue growth. Operating expenses totalled $9.2-million during Q3 2023, including $600,000 of expenses related to staff reductions.

Operational highlights during and subsequent to Q3 2023

Numinus Wellness clinic network

Wellness clinics generated $5-million of revenue during Q3 2023, a 5.5-per-cent sequential increase from $4.7-million in Q2 2023, due mostly to increased client appointments, and a 584.2-per-cent increase compared with $700,000 during the same period last year. Numinus completed more than 21,520 client appointments during the quarter -- including one-on-one and group therapy sessions, neurology-related appointments, paid group programs, ketamine-assisted psychotherapy (KAT), transcranial magnetic stimulation (TMS), and ketamine/Spravato medicine appointments -- representing an 11.2-per-cent increase in clinic appointments compared with more than 19,350 appointments in Q2 2023:

• The average number of appointments per operating day increased by 2.7 per cent (Q3 2023: 331.1 average appointments per day, Q2 2023: 322.5 average appointments per day).
• 8.8 per cent of appointments during Q3 2023 were made by new clients.
• 16.3 per cent of appointments during Q3 2023 were KAT or ketamine/Spravato-medicine related.
• 6.3 per cent of appointments during Q3 2023 were for TMS services.
• At the end of Q3 2023, Numinus had 130 practitioners (Q2 2023: 133) providing client treatments through its wellness clinics and virtual services.

During the fiscal third quarter, Numinus undertook several initiatives to best prepare the company for the future expected approval of MDMA-assisted therapy. First, to facilitate rapid clinic expansion, on April 11, 2023, the company launched its new Numinus Network wellness clinic licensing platform -- a model that provides independent practitioners with the opportunity to own and operate a Numinus-branded full-service clinic. This model is considered integral to achieving efficient scaling of the business, as it leverages resources and infrastructure already functioning within Numinus to expand with minimal capital outlays by the company. Numinus Network clinic owners will receive training on all Numinus therapy protocols, and administrative and marketing support, among other service offerings. On April 11, 2023, Numinus also announced a new partnership with Healing Commercial Real Estate Inc., a health care-focused real estate investment company with deep market knowledge of the psychedelic sector. Through this agreement, Numinus Network licensees will benefit from the option to lease a turnkey, fully functioning Numinus Wellness clinic location, complete with leasehold improvements and clinic infrastructure, directly from Healing CREI. The Numinus Network platform is already gaining a significant amount of interest. To better evaluate markets of high demand, and to further showcase Numinus's clinic offering, on June 22, 2023, Numinus announced that it signed an agreement with HealingMaps. This partnership will drive further clinic awareness and provide Numinus with market data to assist with determining best regions for expansion.

Subsequent to the quarter, on June 15, 2023, Numinus entered into a partnership with the Association for Psychedelic Studies, to provide psychedelic experiential opportunities for practitioners training to offer MDMA-assisted therapy, as part of a clinical study. If the clinical trial application submitted to Health Canada is approved, the MDMA-assisted therapy experiential opportunity would be available only through Numinus.

Numinus clinical research

Revenues from CCR during Q3 2023 were $1-million, a 66.7-per-cent increase compared with the prior quarter. CCR revenue streams are generated through the management of third party clinical trials that use CCR's three clinical research sites. During the third quarter, CCR managed 18 clinical trials, which included 318 clinical trial patient appointments. Included in these were clinical trials for Compass Pathways' phase 3 clinical study of psilocybin therapy, and MindMed's phase 2b study evaluating MM-120 (lysergide D-tartrate) for general anxiety disorder.

Corporate highlights during and subsequent to Q3 2023

Numinus foresees having enough fully trained psychedelic-assisted therapy (PAT) practitioners will be an important factor in scaling the company and the sector. To support growing the number of qualified practitioners, Numinus's training department launched the Numinus certification pathway during the quarter -- a collection of PAT training courses uniquely selected to provide practitioners with complete PAT training, including an experiential component and practicum.

On June 14, 2023, Numinus announced the appointment of Nikhil Handa as chief financial officer, effective June 15, 2023, following a thorough executive search.

Balance sheet and liquidity

Numinus ended the quarter with a total cash balance of $13-million and working capital of $12.9-million.

On May 25, 2023, Numinus announced it had completed a staffing reduction in non-revenue-producing departments, reallocated capital and people resources toward growth initiatives, and reviewed its agency and supplier contracts. As a result of these initiatives, the company believes it has reduced annualized cash expenses by approximately $4.2-million -- extending the company's cash runway past anticipated MDMA-assisted therapy approval.

Numinus's condensed consolidated financial statements for the three and nine months ended May 31, 2023, and related management's discussion and analysis, are available on Numinus's investor relations website and under the company's profile on SEDAR. These documents were prepared in accordance with IFRS (international financial reporting standards).

Conference call and webcast details

Interested parties are invited to participate in the company's Q3 2023 results conference call and webcast occurring on the same day, at 5:30 p.m. ET (2:30 p.m. PT). During the call, Numinus executives will review the company's performance and recent initiatives, and answer questions from analysts.

To listen to the live webcast, please register on-line.

The webcast will also be archived on the events and presentations page of Numinus's investor relations website.

To participate in the live conference call, please use the following dial-in information:

• 1-888-330-3632 (toll-free North America);
• 1-646-960-0837 (international);
• Please ask to participate in Numinus's Q3 2023 results call.

To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.

A replay of the conference call can also be accessed after 8:30 p.m. ET (5:30 p.m. PT) on July 17, 2023, at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until July 31, 2023.

About Numinus Wellness Inc.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- including psychedelic production, research and clinic care -- is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, the company is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

We seek Safe Harbor.